Xin Wang

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Shan-Wen Chen · 1 shared paper, 2025 · strength 0.26
   • Paper SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer. DOI 10.1016/j.isci.2025.113713↗
2. Xiaodong Tian · 1 shared paper, 2025 · strength 0.26
   • Paper SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer. DOI 10.1016/j.isci.2025.113713↗
3. Yinmo Yang · 1 shared paper, 2025 · strength 0.26
   • Paper SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer. DOI 10.1016/j.isci.2025.113713↗
4. Xiaoxue Pan · 1 shared paper, 2025 · strength 0.26
   • Paper SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer. DOI 10.1016/j.isci.2025.113713↗
5. Mingyao Liu · 1 shared paper, 2019 · strength 0.08
   • Paper Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancr… DOI 10.1021/acs.jmedchem.9b00059↗
6. Yunqi Li · 1 shared paper, 2019 · strength 0.08
   • Paper Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancr… DOI 10.1021/acs.jmedchem.9b00059↗
7. Yihua Chen · 1 shared paper, 2019 · strength 0.08
   • Paper Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancr… DOI 10.1021/acs.jmedchem.9b00059↗
8. Zhengfang Yi · 1 shared paper, 2019 · strength 0.08
   • Paper Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancr… DOI 10.1021/acs.jmedchem.9b00059↗
9. Bing Peng · 1 shared paper, 2018 · strength 0.06
   • Paper Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR … DOI 10.1038/s41598-018-36214-5↗
10. Bo Huang · 1 shared paper, 2018 · strength 0.06
    • Paper Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR … DOI 10.1038/s41598-018-36214-5↗
11. Tong‐Chuan He · 1 shared paper, 2018 · strength 0.06
    • Paper Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR … DOI 10.1038/s41598-018-36214-5↗
12. Xubao Liu · 1 shared paper, 2018 · strength 0.06
    • Paper Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR … DOI 10.1038/s41598-018-36214-5↗
13. Zhenyu Ye · 1 shared paper, 2018 · strength 0.06
    • Paper Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR … DOI 10.1038/s41598-018-36214-5↗
14. Chengyi Sun · 1 shared paper, 2015 · strength 0.04
    • Paper Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inac… DOI 10.1016/j.canlet.2014.11.026↗
15. Xu Li · 1 shared paper, 2015 · strength 0.04
    • Paper Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inac… DOI 10.1016/j.canlet.2014.11.026↗
16. Xingjun Guo · 1 shared paper, 2015 · strength 0.04
    • Paper Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inac… DOI 10.1016/j.canlet.2014.11.026↗
17. Chengjian Shi · 1 shared paper, 2015 · strength 0.04
    • Paper Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inac… DOI 10.1016/j.canlet.2014.11.026↗
18. Jianxin Jiang · 1 shared paper, 2015 · strength 0.04
    • Paper Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inac… DOI 10.1016/j.canlet.2014.11.026↗
19. Renyi Qin · 1 shared paper, 2015 · strength 0.04
    • Paper Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inac… DOI 10.1016/j.canlet.2014.11.026↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.